Banca de DEFESA: DANIEL DE JESUS RIBEIRO

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
DISCENTE : DANIEL DE JESUS RIBEIRO
DATA : 14/07/2020
HORA: 14:30
LOCAL: NUTS – Núcleo Universitário de Telessaúde - HUPES/UFBA - Plataforma Conferência Web da RNP – O link 
TÍTULO:

Effectiveness and Safety of Ranibizumab Treatment in a University Hospital

PALAVRAS-CHAVES:

Effectiveness, Safety, Ranibizumab

PÁGINAS: 55
GRANDE ÁREA: Ciências da Saúde
ÁREA: Farmácia
RESUMO:

Title: Effectiveness and safety in the treatment with ranibizumab in a University Hospital. Objectives: to evaluate the effectiveness and safety of ranibizumab in the treatment of retina deseases in a university hospital. Methodology: data from patients treated with ranibizumab were collected through interviews with participants and information obtained from medical records, the main measures of effectiveness were the variation in visual acuity (VA) and changes in central retinal thickness (CRT) . All adverse events that occurred during treatment were recorded for safety assessment. Results: a total of 103 patients were included in the study and a number of 154 treated eyes. The mean age found was 67.8 years and most patients received treatment for diabetic macular edema, followed by treatment for retinal venous occlusion. The mean variation in VA represented a loss of 0.9 letters and the mean variation in the CRT found was a reduction of 12.6 µm, indicating stability in the macular edema of the treated eyes. Conclusions: The information collected in this research demonstrated that ranibizumab had a lower degree of effectiveness in the treatment of neovascular diseases of the retina, due to little variation in visual acuity and in the thickness measurements of the central retina in the treated patients. The low number of applications of the drug and the interval between applications may be the factors that contributed significantly to the low results of effectiveness in the population studied. With regard to safety aspects, the vast majority of adverse events reported were related to the medication application procedure.

MEMBROS DA BANCA:
Presidente - 096.219.544-87 - LUCIA DE ARAUJO COSTA BEISL NOBLAT - UFRN
Externo à Instituição - NEY CRISTIAN AMARAL BOA SORTE - UNEB
Externo ao Programa - 2556460 - PABLO DE MOURA SANTOS
Externo ao Programa - 286129 - PAULO AFONSO BATISTA DOS SANTOS